Seattle Genetics Stock News

Seagen Inc (NASDAQ: SGEN) has revealed new data from exploratory analyses from the HER2CLIMB trial of Tukysa (tucatinib) combined with trastuzumab & capecitabine in HER2-positive metastatic breast

Having fallen more than 22% over the last month, Seagen Inc (NASDAQ: SGEN) shares are now trading down about 15% year-to-date. With Seagen stock seemingly stuck in a downtrend, Virtus Investment Partn

Private Advisor Group LLC boosted its stake in shares of Seagen Inc. (NASDAQ:SGEN) by 48.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,738 shares of the biotechnology companys stock after acquiring an additional 5,129 shares during the quarter. Private []

Seagen Inc. (NASDAQ:SGEN) Director Bros. Advisors Lp Baker sold 301,444 shares of the firms stock in a transaction that occurred on Tuesday, November 30th. The stock was sold at an average price of $160.33, for a total transaction of $48,330,516.52. The transaction was disclosed in a document filed with the SEC, which is available through []

Moser Wealth Advisors LLC lifted its position in shares of Seagen Inc. (NASDAQ:SGEN) by 1.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,580 shares of the biotechnology companys stock after acquiring an additional 82 shares during the quarter. Seagen accounts for []

Comerica Bank cut its holdings in shares of Seagen Inc. (NASDAQ:SGEN) by 3.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,630 shares of the biotechnology companys stock after selling 324 shares during the quarter. Comerica Banks holdings in Seagen were []

Wall Street brokerages forecast that Seagen Inc. (NASDAQ:SGEN) will report earnings of ($0.74) per share for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for Seagens earnings, with the lowest EPS estimate coming in at ($1.15) and the highest estimate coming in at ($0.28). Seagen reported earnings per share of $0.90 []

Seagen Inc. (NASDAQ:SGEN) shares, rose in value on Friday, 11/26/21, with the stock price down by -2.14% to the previous days close as strong demand from buyers drove the stock to $169.50. Actively observing the price movement in the last trading, the stock closed the session at $173.20, falling within a range of $169.055 and Metrics That Matter About Seagen Inc. (NASDAQ: SGEN) Read More »

Analysts expect Seagen Inc. (NASDAQ:SGEN) to report ($0.76) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Seven analysts have issued estimates for Seagen’s earnings, with the highest EPS estimate coming in at ($0.28) and the lowest estimate coming in at ($1.15). Seagen posted earnings of $0.90 per share in the same […]

Equities analysts forecast that Seagen Inc. (NASDAQ:SGEN) will post $407.59 million in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have made estimates for Seagens earnings, with the highest sales estimate coming in at $435.42 million and the lowest estimate coming in at $396.66 million. Seagen reported sales of $601.29 million []

Parametric Portfolio Associates LLC increased its stake in shares of Seagen Inc. (NASDAQ:SGEN) by 7.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 227,033 shares of the biotechnology companys stock after buying an additional 16,107 shares during the period. Parametric Portfolio Associates LLCs holdings in []

Positive trial results regarding the company's pipeline are buoying the stock's price.

Sawtooth Solutions LLC lifted its holdings in shares of Seagen Inc. (NASDAQ:SGEN) by 21.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,089 shares of the biotechnology companys stock after acquiring an additional 714 shares during the period. Sawtooth []

Man Group plc increased its position in Seagen Inc. (NASDAQ:SGEN) by 338.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,004 shares of the biotechnology companys stock after purchasing an additional 20,848 shares during the quarter. Man Group plcs []

The best may be yet to come for these companies.